Xoft Inc., of Sunnyvale, Calif., today announced its Axxent Electronic Brachytherapy System has received expanded clearance from the U.S. Food and Drug Administration.

Previously cleared for accelerated treatment of early stage breast cancer, the proprietary technology platform is now cleared for use in the delivery of localized, non-radioactive, isotope-free radiation treatment in minimally shielded clinical settings for other cancers or conditions where radiation therapy is indicated. The system was developed to deliver the non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.

The company is working to extend the use of electronic brachytherapy to endometrial and rectal indications.